Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo?

Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!

In This Episode:
Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?
Dermatomyositis: Consequences of misdiagnosis and delayed diagnosis
Vitiligo: Could hydroxychloroquine be a game-changer over NBUVB?
Skin Inflammation: A key driver of food allergy
Pemphigoid: Insights into immunotherapy-induced cases
Premenstrual Rashes: Managing flares in atopic

1.  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
2.  Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis
3.  Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial
4.  Skin damage signals mediate allergic sensitization to spatially unlinked antigen
5.  Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid
6.  The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review
7.  Nickel contact allergy and menstrual cycle
8.  Autoimmune progesterone dermatitis: Update and insights

Derms on Drugs is produced by ⁠⁠Scholars in Medicine.com